EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country

Hikmat Abdel-Razeq iD, Baha Sharaf iD, Suhaib Khater, Huda Jafar Baidoun iD, Hira Bani Hani, Ayat Taqash iD, Osama El Khatib iD, Sarah Edaily iD, Mahmoud Abunasser iD, Faris Tamimi iD, Yosra Nabeel Al-Masri, Tamer Moh'd Waleed Al-Batsh und 3 weitere

ImmunoTargets and Therapy · 2024-09 · Volume 13 · 501-512

DOI: 10.2147/itt.s479153 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ImmunoTargets and Therapy, 2024-09. Verfasst von Hikmat Abdel-Razeq und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Hematology and Medical Oncology, King Hussein Cancer Center, Amman, Jordan. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

CDK4/6 inhibitorsMBCaromatase inhibitorsfulvestrantmetastatic breast cancerribociclib

Autor:innen und Institutionen

  • Department of Internal Medicine, Section of Hematology and Medical Oncology, King Hussein Cancer Center, Amman, Jordan.
  • School of Medicine, the University of Jordan, Amman, Jordan.
  • Office of Scientific Affairs and Research. King Hussein Cancer Center, Amman, Jordan.

ORCID-Profile: Hikmat Abdel-Razeq, Baha Sharaf, Huda Jafar Baidoun, Ayat Taqash, Osama El Khatib, Sarah Edaily, Mahmoud Abunasser, Faris Tamimi

Zitieren

APA

Abdel-Razeq, H., Sharaf, B., Khater, S., Baidoun, H. J., Bani Hani, H., Taqash, A., El Khatib, O., Edaily, S., Abunasser, M., Tamimi, F., Al-Masri, Y. N., Al-Batsh, T. M. W., Zayed, A., Ghatasheh, T., & Radaideh, T. (2024). Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country. ImmunoTargets and Therapy, Volume 13, 501-512. https://doi.org/10.2147/itt.s479153

Vancouver

Abdel-Razeq H, Sharaf B, Khater S, Baidoun HJ, Bani Hani H, Taqash A, et al. Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country. ImmunoTargets and Therapy. 2024;Volume 13:501-512. doi:10.2147/itt.s479153

BibTeX
@article{AbdelRazeq2024,
  author = {Abdel-Razeq, Hikmat and Sharaf, Baha and Khater, Suhaib and Baidoun, Huda Jafar and Bani Hani, Hira and Taqash, Ayat and El Khatib, Osama and Edaily, Sarah and Abunasser, Mahmoud and Tamimi, Faris and Al-Masri, Yosra Nabeel and Al-Batsh, Tamer Moh'd Waleed and Zayed, Anas and Ghatasheh, Tala and Radaideh, Tala},
  title = {Clinical Outcomes of Patients Treated with Ribociclib in Combination with Aromatase Inhibitors or Fulvestrant for HR-Positive, HER2-Negative Metastatic Breast Cancer, Real-World Data from a Low-Resourced Country},
  journal = {ImmunoTargets and Therapy},
  year = {2024},
  volume = {Volume 13},
  pages = {501--512},
  doi = {10.2147/itt.s479153}
}
Kostenlos starten →